by Dennis Thompson
Researchers pulled the plug early on the latest failed clinical trial, after patients' brain power continued to decline even though the amyloid beta blocker verubecestat successfully lowered amyloid levels in their brains and spinal fluid. The disappointing verubecestat results appear in the April 11 issue of the New England Journal of Medicine, alongside a research letter announcing similarly negative preliminary findings from the clinical trial of another amyloid blocker called atabecestat. These negative results jibe with those of earlier trials, and present "pretty strong evidence that amyloid-lowering is the wrong target," said Dr. David Knopman. He's a professor of neurology with the Mayo Clinic who wrote an editorial accompanying the new reports.
Reach: HealthDay distributes its health news to media outlets several times each day and also posts its news on its website, which receives more than 379,000 unique visitors each month. HealthDay stories appears in 40 newspapers around the world and on television stations in 4 of the 10 markets and is also used by hospitals, clinics, private practices, non-profit organizations and government agencies.
Additional coverage: Alzforum
Context: David Knopman, M.D. is a Mayo Clinic neurologist. Dr. Knopman is involved in research in late-life cognitive disorders, such as mild cognitive impairment and dementia. Dr. Knopman's specific interests are in the very early stages of Alzheimer's disease, in cognitive impairment due to stroke (cerebrovascular disease) and in cognitive impairment due to frontotemporal degeneration. He is involved in epidemiology, clinical trials and diagnostic studies of these disorders. You can read more about his research here.
Contact: Susan Barber Lindquist